It was just a couple months ago the company made this acquisition to grow the corporation and spent $800 Million, but as you can see when restructuring come in to play with algorithms for profit, this does not do much for those in areas to where growth is not anticipated.
Medtronic Acquires Hypertension Device Used to Deaden Nerves In the Kidney Area to Control Blood Pressure-Acquisitions Seen As Path Way For Growth
One other item worth a mention is their medical device division that is now connecting with electronic medical records. You can read more about CareLink networks at the link below. As much as we think about the company being in the cardiology business, they have a lot more going on with connecting to medical records and something else for the hospital CIO to put under his project hat.
Medtronic CareLink(R) Network Goes Cellular – Devices That Report Data Connecting to EHR Records With HL7
If you are not implanted, you will be carrying one, wearing one, or sticking one on your body somewhere it seems. Next with aggregation we will see multi purpose devices too, one that may serve 2-3 purposes, and then of course there’s the question of the software being correct with no bugs before we track off into our brave new world here. 2000 certainly appears to be shaping up as the “decade of the sensors”. Medtronic is ready to get connected with EHRs and EMRs to send the data with their Paceart System to integrate.
So if you have not thought about the company emerging as a player in the Health IT business, think again and perhaps this might be where some of the focus is shifting with algorithms and devices that monitor and create data trails. I am just merely speculating relative to what I see and read in the news today. BD
Medtronic Inc. (NYSE:MDT) plans to lay off up to 5 percent of its workers in a bid to shore up its long-term prospects, despite reporting strong third-quarter sales and earnings numbers.
The news means job losses for between 1,500 and 2,000 workers worldwide. The company said the move is meant to "align its cost structure to current market conditions and continue to position Medtronic for long-term sustainable growth."
Medtronic posted profits of $924 million, or 86 cents per diluted share, on sales of $3.96 billion for the three months ended Jan. 28. That's a 2.9 percent top-line increase and an 11.2 percent boost to the bottom line when compared with earnings of $831 million, or 75 cents per diluted share, on sales of $3.85 billion during the same period last year.